| 形态 | Liquid |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | Vascular Endothelial Growth Factor Receptor 3 fusi |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | Vascular endothelial growth factor C, VEGFC, Flt4-L, VEGF-C, Vascular endothelial growth factor-related protein, VRP, Flt4 ligand, Vascular endothelial growth factor D, VEGF-D, FIGF, VEGFD, c-Fos-indu |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | P49767 & O43915 |
|---|
| 背景信息 | Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.
|
|---|
| 别名 | OPT-302, solubleVEGFR-3, sozinibercept, VGX-300 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|